Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;10(9):2664-73.
doi: 10.4161/hv.29683.

Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis

Jose Rey-Ladino  1 , Allen G P Ross, Allan W Cripps
Affiliations
Review

Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis

Jose Rey-Ladino et al. Hum Vaccin Immunother. 2014.

Abstract

This review examines the immunity, immunopathology, and contemporary problems of vaccine development against sexually transmitted Chlamydia trachomatis. Despite improved surveillance and treatment initiatives, the incidence of C. trachomatis infection has increased dramatically over the past 30 years in both the developed and developing world. Studies in animal models have shown that protective immunity to C. trachomatis is largely mediated by Th1 T cells producing IFN-γ which is needed to prevent dissemination of infection. Similar protection appears to develop in humans but in contrast to mice, immunity in humans may take years to develop. Animal studies and evidence from human infection indicate that immunity to C. trachomatis is accompanied by significant pathology in the upper genital tract. Although no credible evidence is currently available to indicate that autoimmunity plays a role, nevertheless, this underscores the necessity to design vaccines strictly based on chlamydial-specific antigens and to avoid those displaying even minimal sequence homologies with host molecules. Current advances in C. trachomatis vaccine development as well as alternatives for designing new vaccines for this disease are discussed. A novel approach for chlamydia vaccine development, based on targeting endogenous dendritic cells, is described.

Keywords: Chlamydia trachomatis; dendritic cells; immunity; pathology; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Model of C. trachomatis immunity and pathology. Following cervical infection, an early acute inflammatory response occurs, characterized by secretion of pro-inflammatory cytokines and recruitment of immune cells. Cytokine production by immune cells synergizes with ongoing immune responses that ultimately controls infection but also may cause pathology. C. trachomatis can ascend via the endometrium to the upper genital tract. As a consequence, local pro-inflammatory mediators and cytokines are produced. In an attempt to control the infection, Chlamydia-specific T cells and corresponding cytokines infiltrate the oviduct. These inflammatory responses, if persistent, may lead to fibrosis, scarring, and reproductive sequelae. Abbreviations: MMP, matrix metalloproteinases; SIgA, secretary immunoglobulin A; EBS, Chlamydia elementary bodies; MIP2, macrophage inflammatory protein-2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Belland R, Ojcius DM, Byrne GI. Chlamydia. Nat Rev Microbiol 2004; 2:530-1; PMID:15248311; http://dx.doi.org/10.1038/nrmicro931 - DOI - PubMed
    1. World Health Organization Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates [Internet]. Geneva: World Health Organization; 2001. [cited 2012 Aug 8]. Available from: http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf
    1. Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med 2003; 349:2424-30; PMID:14681509; http://dx.doi.org/10.1056/NEJMcp030542 - DOI - PubMed
    1. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005; 5:149-61; PMID:15688042; http://dx.doi.org/10.1038/nri1551 - DOI - PubMed
    1. Centers for Disease Control and Prevention Sexually transmitted disease surveillance 2009 [Internet]. Atlanta, US: Division of preventive STD prevention, Department of Health and Human Services, CDCP; 2010. [cited 2012 Aug 12]. Available from: http://www.cdc.gov/std/stats09/surv2009-Complete.pdf

MeSH terms

LinkOut - more resources